OCT 29·SEC EDGARHigh
Portman David J. purchased 3,149,470 shares of LONA (indirect holdings)
Portman David J. purchased 3,149,470 indirectly-held shares of LeonaBio, Inc. (LONA) at $3149.47 on 2026-10-26.
StockNASDAQ · US · USDHealthcare · BIOTECHNOLOGY
$LONA
LeonaBio, Inc.
LeonaBio is a clinical-stage biopharmaceutical company developing drug candidates for treatment-resistant metastatic breast cancer, amyotrophic lateral sclerosis (ALS) and other neurological conditions. Its pipeline includes lasofoxifene, an oral small-molecule therapy being evaluated in a Phase 3 trial for metastatic breast cancer with ESR1 mutations, and ATH-1105, a small molecule designed to modulate the neurotrophic HGF system and being developed for ALS. The company has also studied ATH-1020 for neurological indications and has early compounds targeting other molecular targets. LeonaBio develops programs internally and acquires or in-licenses drug rights. It aims to commercialize candidates following regulatory approval and is reviewing partnership or other arrangements. LeonaBio is based in Bothell, Washington.
Price · $LONAvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $LONA in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 1 txs
- Sells
- — 0 txs
Portman David J.1× · —
10b5-1 share of filings0%
Top stories · $LONAMore →
SEP 22·SEC EDGAR 8-K
In December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock
LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3
AUG 28·theglobeandmail.com
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)
Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.
LONA sentiment & insider activity
Recent LONA coverage spans corporate actions, earnings and insider activity.
In the last 30 days, LONA insiders filed 1 SEC Form 4 transaction — 1 purchase and no sales. The most active reporter was Portman David J. with 1 filing.
What's driving LONA
Large insider purchase signals confidence and may drive short‑term buying pressure.
Exercisable warrants may trigger significant cash inflow and dilution, likely moving the stock price.
Analyst maintains bullish stance with a significant upside target.
The beat reduces near-term downside risk, but the bigger driver is continued execution toward ELAINE-3 recruitment completion in Q4 2026 and topline in H2 2027.
Near-term trading focus is ELAINE-3 enrollment progress and the company’s funding runway via cash-exercisable warrants, with additional pipeline updates.
AlphAI scores every news story that mentions LONA with an AI model for sentiment and relevance, and aggregates insider trades from LeonaBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $LONA
Score
Portman David J. purchased 3,149,470 shares of LONA (indirect holdings)
Portman David J. purchased 3,149,470 indirectly-held shares of LeonaBio, Inc. (LONA) at $3149.47 on 2026-10-26.
1 min readIn December 2025, as part of a private placement, LeonaBio, Inc. issued warrants to purchase an aggregate of 23,031,494 shares of its common stock
LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. In December 2025, as part of a private placement, LeonaBio, Inc. (the “Company”) issued warrants to purchase an aggregate of 23,031,494 shares of its common stock (the “Series A Common Warrants”). The Series A Common Warrants have an exercise price of $6.3
1 min read
Analysts Offer Insights on Healthcare Companies: NeoGenomics (NEO), LeonaBio (LONA) and Solid Biosciences (SLDB)
Analysts from Piper Sandler and Cantor Fitzgerald maintained Buy ratings on NeoGenomics (NEO), LeonaBio (LONA), and Solid Biosciences (SLDB). NeoGenomics has a $21.00 target, LeonaBio a $20.00 target, and Solid Biosciences a $26.00 target. Consensus ratings are Moderate Buy for NEO and Strong Buy for LONA and SLDB, with respective average targets of $18.33, $17.33, and $19.17.
2 min read
LeonaBio beats Q2 loss forecast as Phase 3 ELAINE-3 trial advances
LeonaBio (NASDAQ:LONA) reported a Q2 loss of $0.80 per share, smaller than analysts’ $1.12 forecast. Net loss rose to $19.0 million from $7.0 million a year earlier. Phase 3 ELAINE-3 enrollment nears 600 target, with 495 patients enrolled and topline results expected in H2 2027. Cash fell to $51.1 million from $88.3 million.
4 min readLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update
LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 LeonaBio Reports Second Quarter 2026 Financial Results and Provides Business Update On Track to Complete Enrollment of Phase 3 ELAINE-3 Clinical Trial of Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer in 4Q 2026 with Topline D
6 min readLeonaBio, Inc. (LONA): Submission of Matters to a Vote of Security Holders
LeonaBio, Inc. (LONA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001620463 0001620463 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,
1 min read